Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
GRAVITAS-309: Itacitinib plus corticosteroids as initial treatment for chronic graft-versus-host disease
2018-001606-29Phase 2Completed
- Sponsor
- Incyte
- Start
- Jan 2019
- Modality
- Small Molecules
- Countries
- 1
01
Overview
Phase 2 trial of itacitinib in chronic graft-versus-host disease (cGVHD), sponsored by Incyte. Primary endpoint: Dose-limiting toxicities through Day 28 (Part 1). Started Jan 2019; status: completed.
02
Drugs
itacitinib
03
Conditions
chronic graft-versus-host disease (cGVHD)
Beyond the preview
Go deeper on 2018-001606-29.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2018-001606-29.